Shock · 2020 · 20 citations · 55 references
Life SciencesImmunologyPharmacologyAdaptive ImmunityImmunopharmacologyImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint ModulationImmune Checkpoint RegulationImmune CheckpointsSepsis PathophysiologyCheckpoint Antagonist TherapyCheckpoint Inhibitor AntibodiesHost Immune SuppressionImmune Suppression MechanismsImmune-mediated Adverse EventsPd-1 SignalingProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Cell Death Protein 1 Inhibitors
ABSTRACT: Sepsis-induced immunosuppression involves both innate and adaptive immunity and is associated with the increased expression of checkpoint inhibitors, such as programmed cell-death protein 1 (PD-1). The expression of PD-1 is associated with poor outcomes in septic patients, and in models of sepsis, blocking PD-1 or its ligands with antibodies increased survival and alleviated immune suppression. While inhibitory antibodies are effective, they can lead to immune-related adverse events (irAEs), in part due to continual blockade of the PD-1 pathway, resulting in hyperactivation of the immune response. Peptide-based therapeutics are an alternative drug modality that provide a rapid pharmacokinetic profile, reducing the incidence of precipitating irAEs. We recently reported that the potent, peptide-based PD-1 checkpoint antagonist, LD01, improves T-cell responses. The goal of the current study was to determine whether LD01 treatment improved survival, bacterial clearance, and host immunity in the cecal-ligation and puncture (CLP)-induced murine polymicrobial sepsis model. LD01 treatment of CLP-induced sepsis significantly enhanced survival and decreased bacterial burden. Altered survival was associated with improved macrophage phagocytic activity and T-cell production of interferon-γ. Further, myeloperoxidase levels and esterase-positive cells were significantly reduced in LD01-treated mice. Taken together, these data establish that LD01 modulates host immunity and is a viable therapeutic candidate for alleviating immunosuppression that characterizes sepsis and other infectious diseases.
55
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Sydney R. Gordon, Roy L. Maute, Ben W. Dulken et al. · Nature · 2017 · 2.3K citations · Full text
Life Sciences, Immunology, Oncology +16
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
E. John Wherry, Sang‐Jun Ha, Susan M. Kaech et al. · Immunity · 2007 · 2.1K citations